NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

If Doc, and earlier speculative alternatives by RK, myself and a few others, are correct; if Germany had to halt for efficacy because of more sensitivity to placebo dosing, then it might make sense Fraunhofer would be the one to state final analysis begins after last patient in overall trial is dosed. (Which likely happened early May 2018 or sooner.)

The reason Fraunhofer might be likely to make that public is perhaps two-fold. 1. Germany's clinicaltrial site states trial ends at last patient last visit, so perhaps Fraunhofer wanted to clarify more specificity regarding when final analysis occurred. 2. German regulatory agencies were pointed to by NWBO for slowing down Fraunhofer's startup in the trial, and if Germany bowed out early for efficacy, as some suspect as a possibility, they might feel obliged to point back to the fact the trial will be analyzed right after the last patient receives their tenth (placebo and/or treatment) dose.

Besides, NWBO has had so many past deadlines, I tend to look to some other frame of reference for "forward looking statements," if you know what I mean.